NCT06573411

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy: A Prospective, Randomized, Controlled, Multicenter Clinical Study

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 116 (estimated)
• Sponsor: First Affiliated Hospital, Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, randomized, multicenter, controlled trial. One hundred sixteen patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups. The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD. Control patients will be administered maximum tolerable dose of ACEI/ARB. The primary endpoint is the relative change in urinary protein content from baseline to 6 months.

Detailed description

After more than 4 weeks of maximum tolerated dose of ACEI/ARB, the patients will be randomly divided into the control and intervention groups in a 1:1 ratio. The intervention group will then be administered finerenone 20 mg QD, while control cases will continue on their ACEI/ARB therapy.

Conditions

• Primary Membranous Nephropathy

Interventions

Type	Name	Description
DRUG	ACEI/ARB+ finerenone	The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD.
DRUG	ACEI/ARB	Control patients will be administered maximum tolerable dose of ACEI/ARB.

Timeline

• Start date: 2024-09-30
• Primary completion: 2026-10-30
• Completion: 2026-10-30
• First posted: 2024-08-27
• Last updated: 2026-04-08

Locations

1 site across 1 country: China